Apellis Pharmaceuticals I... (APLS)
NASDAQ: APLS
· Real-Time Price · USD
17.29
-0.52 (-2.92%)
At close: May 09, 2025, 3:59 PM
17.77
2.78%
Pre-market: May 12, 2025, 04:04 AM EDT
Apellis Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Licensing And Other Revenue Revenue | 71.41M | 30.31M | 10.33M | 51.42M |
| Licensing And Other Revenue Revenue Growth | +135.61% | +193.42% | -79.91% | n/a |
| Product Revenue | 709.95M | 366.28M | 65.09M | 15.15M |
| Product Revenue Growth | +93.83% | +462.71% | +329.74% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 121.48M | 121.98M | 127.63M | 129.06M | 141.7M | 145.65M | 111.37M | 102.09M | 84.37M | 78.41M | 63.2M | 51.19M | 41.46M | 45.76M | 48.97M | 40.58M | 44.49M | 36.99M | 28.41M | 29.5M | 27.47M | 18.63M | 12.78M | 8.17M | 6.39M | 6.27M | 5.95M | 4.04M | 4.86M | 2.07M | 1.71M | 1.82M | 1.09M | 1M | 1.11M | 1.11M | 3.04M | 1.41M | 950.66K | 950.66K |
| Selling, General, and Administrative Revenue Growth | -0.41% | -4.43% | -1.11% | -8.92% | -2.71% | +30.77% | +9.09% | +21.01% | +7.60% | +24.05% | +23.47% | +23.46% | -9.40% | -6.54% | +20.67% | -8.79% | +20.28% | +30.19% | -3.69% | +7.41% | +47.45% | +45.79% | +56.39% | +27.85% | +2.01% | +5.33% | +47.40% | -16.97% | +134.62% | +21.11% | -6.10% | +67.52% | +8.71% | -9.75% | 0.00% | -63.58% | +115.34% | +48.63% | 0.00% | n/a |
| Research and Development Revenue | 76.35M | 88.57M | 77.95M | 84.7M | 69.28M | 79.42M | 95.66M | 110.03M | 99.42M | 95.21M | 101.66M | 90.94M | 103.18M | 87.73M | 145.94M | 84.01M | 50.34M | 93.21M | 87.09M | 69.28M | 78.47M | 51.32M | 50.7M | 40.48M | 30.81M | 29.54M | 27.54M | 17.4M | 13.13M | 9.52M | 10.42M | 7.23M | 5.59M | 6.23M | 5.58M | 5.58M | 3.93M | 3.75M | 3.03M | 3.03M |
| Research and Development Revenue Growth | -13.79% | +13.63% | -7.97% | +22.26% | -12.77% | -16.97% | -13.06% | +10.67% | +4.43% | -6.35% | +11.78% | -11.86% | +17.61% | -39.89% | +73.72% | +66.90% | -45.99% | +7.02% | +25.71% | -11.71% | +52.91% | +1.22% | +25.24% | +31.40% | +4.29% | +7.27% | +58.24% | +32.51% | +37.98% | -8.68% | +44.13% | +29.32% | -10.31% | +11.79% | 0.00% | +41.95% | +4.88% | +23.68% | 0.00% | n/a |